EUVIMEDEUVIMED entdecken
Crossref

Optimization of 4-Aniline Substituted Pyrido[3,2- d ]pyrimidine Derivatives as Pim/Mnk Dual Inhibitors with Antileukemia Activity

Kun Xing, Shujun Li, Shuwei Zuo, Huimin Zhang, Fuyao Zhang, Jinghuan Li, Jiachen Wen iD, Dan Liu, Samuel Waxman, Yongkui Jing iD, Min Huang iD, Jingyi Zhang und 1 weitere

Journal of Medicinal Chemistry · 09.04.2026 · 69 (7) · 8298-8315

DOI: 10.1021/acs.jmedchem.5c03328 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 24.03.2026. Verfasst von Kun Xing und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-pim-1, Intracellular Signaling Peptides and Proteins, Protein Serine-Threonine Kinases, Pyrimidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Liaoning Revitalization Talents Program, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-pim-1Intracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesPyrimidinesAntineoplastic AgentsProtein Kinase InhibitorsLeukemiaAniline CompoundsHumansAnimalsCell Line, TumorStructure-Activity RelationshipMiceCell ProliferationApoptosis

Substanzen

Proto-Oncogene Proteins c-pim-1Intracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesPyrimidinesAntineoplastic AgentsProtein Kinase InhibitorsMKNK1 protein, humanMKNK2 protein, humanAniline CompoundsPIM1 protein, human

Autor:innen und Institutionen

  • Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
  • Liaoning Key Laboratory of Targeting Drugs for Hematological Malignancies, Shenyang Pharmaceutical University, Shenyang 110016, China.
  • The Division of Hematology/Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.

ORCID-Profile: Jiachen Wen, Yongkui Jing, Min Huang, Linxiang Zhao

Förderung

  • Liaoning Revitalization Talents Program
  • National Natural Science Foundation of China

Zitieren

APA

Xing, K., Li, S., Zuo, S., Zhang, H., Zhang, F., Li, J., Wen, J., Liu, D., Waxman, S., Jing, Y., Huang, M., Zhang, J., & Zhao, L. (2026). Optimization of 4-Aniline Substituted Pyrido[3,2- d ]pyrimidine Derivatives as Pim/Mnk Dual Inhibitors with Antileukemia Activity. Journal of Medicinal Chemistry, 69(7), 8298-8315. https://doi.org/10.1021/acs.jmedchem.5c03328

Vancouver

Xing K, Li S, Zuo S, Zhang H, Zhang F, Li J, et al. Optimization of 4-Aniline Substituted Pyrido[3,2- d ]pyrimidine Derivatives as Pim/Mnk Dual Inhibitors with Antileukemia Activity. Journal of Medicinal Chemistry. 2026;69(7):8298-8315. doi:10.1021/acs.jmedchem.5c03328

BibTeX
@article{Xing2026,
  author = {Xing, Kun and Li, Shujun and Zuo, Shuwei and Zhang, Huimin and Zhang, Fuyao and Li, Jinghuan and Wen, Jiachen and Liu, Dan and Waxman, Samuel and Jing, Yongkui and Huang, Min and Zhang, Jingyi and Zhao, Linxiang},
  title = {Optimization of 4-Aniline Substituted Pyrido[3,2- d ]pyrimidine Derivatives as Pim/Mnk Dual Inhibitors with Antileukemia Activity},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {7},
  pages = {8298--8315},
  doi = {10.1021/acs.jmedchem.5c03328}
}
Kostenlos starten →